Exact Mass: 598.3115

Avermectin A1a aglycone

C35H50O8 (598.3506)

12-Ethyl-8-isobutyl-3-vinylbacteriochlorophyllide d

C36H38MgN4O3 (598.2794)

A chlorophyllide obtained by hydrolysis of the terpenoid ester moiety of 12-ethyl-8-isobutyl-3-vinylbacteriochlorophyll d.

Hematoporphyrin IX

C34H38N4O6 (598.2791)

Iron-free derivatives of heme with 4 methyl groups, 2 hydroxyethyl groups and 2 propionic acid groups attached to the pyrrole rings. Some of these phosphosensitizing agents are used in the phototherapy of malignant neoplasms. -- Pubchem [HMDB] Iron-free derivatives of heme with 4 methyl groups, 2 hydroxyethyl groups and 2 propionic acid groups attached to the pyrrole rings. Some of these phosphosensitizing agents are used in the phototherapy of malignant neoplasms. -- Pubchem.

LysoPI(18:1(9Z)/0:0)

C27H51O12P (598.3118)

LysoPI(18:1(9Z)/0:0) is a lysophosphatidylinositol. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylinositols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPI(18:1(9Z)/0:0), in particular, consists of one chain of oleic acid at the C-1 position.

H-Phe-D-met-arg-phe-NH2

C29H42N8O4S (598.305)

Hematoporphyrin

C34H38N4O6 (598.2791)

PI(18:1(9Z)/0:0)

C27H51O12P (598.3118)

Rupintrivir

C31H39FN4O7 (598.2803)

PA(8:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C31H51O9P (598.3271)

PA(8:0/20:4(6E,8Z,11Z,14Z)+=O(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(6E,8Z,11Z,14Z)+=O(5)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 5-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/8:0)

C31H51O9P (598.3271)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)+=O(5)/8:0), in particular, consists of one chain of one 5-oxo-eicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C31H51O9P (598.3271)

PA(8:0/20:4(5Z,8Z,11Z,13E)+=O(15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(5Z,8Z,11Z,13E)+=O(15)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 15-oxo-eicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/8:0)

C31H51O9P (598.3271)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)+=O(15)/8:0), in particular, consists of one chain of one 15-oxo-eicosatetraenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 18-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/8:0)

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/8:0), in particular, consists of one chain of one 18-hydroxyleicosapentaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 15-hydroxyleicosapentaenyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/8:0)

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/8:0), in particular, consists of one chain of one 15-hydroxyleicosapentaenyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 12-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/8:0)

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/8:0), in particular, consists of one chain of one 12-hydroxyleicosapentaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C31H51O9P (598.3271)

PA(8:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 5-hydroxyleicosapentaenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/8:0)

C31H51O9P (598.3271)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/8:0), in particular, consists of one chain of one 5-hydroxyleicosapentaenoyl at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Cussoracoside F

C31H50O11 (598.3353)

Taxawallin D

C33H42O10 (598.2778)

12-O-Methylvolkensin

C34H46O9 (598.3142)

Amotsangin B

C33H42O10 (598.2778)

Cyl-2

C32H46N4O7 (598.3366)

Bacobitacin B

C34H46O9 (598.3142)

13-O-Acetyl-brevifoliol

C33H42O10 (598.2778)

Gambogin

C38H46O6 (598.3294)

L006181

C30H42N6O7 (598.3115)

FA-70D

C30H42N6O7 (598.3115)

Cinnafragrin D

C34H46O9 (598.3142)

13-Acetylbrevifoliol

C33H42O10 (598.2778)

Swietmanin A

C33H42O10 (598.2778)

Salannol 3-acetate

C34H46O9 (598.3142)

Phosphatidylinositol lyso 18:1

C27H51O12P (598.3118)

HEMATOPORPHYRIN

C34H38N4O6 (598.2791)

D011838 - Radiation-Sensitizing Agents > D017319 - Photosensitizing Agents > D006415 - Hematoporphyrins C1420 - Photosensitizing Agent D003879 - Dermatologic Agents

Euphoheliosnoid C

C33H42O10 (598.2778)

3-(4-Acetoxy-2-hydroxy-2,6,6-trimethylcyclohexylidene)-1-methylprop-2-enyl 2,3,4,6-Tetra-O-acetyl-beta-D-glucopyranoside

C29H42O13 (598.2625)

6alpha-Acetoxyhavanensin acetate

C34H46O9 (598.3142)

anodendrosin B

C29H42O13 (598.2625)

3-(Hydrogen suberoyl)-Cinobufagin

C34H46O9 (598.3142)

15-??-Hydroxylineolon 3-O-??-D-glucopyranosyl-(1鈥樏傗垎4)-??-D-oleandropyranosyl-(1鈥樏傗垎4)-??-D-digitoxopyranosyl-(1鈥樏傗垎4)-??-D-cymaropyranosyl-(1鈥樏傗垎4)-??-D-cymaropyranoside

C26H46O15 (598.2837)

Picrasinoside D

C30H46O12 (598.2989)

6beta,7beta-diacetoxy-8,13-epoxy-labd-14-en-11-one-1alpha-O-beta-glucopyranoside|forskoditerpenoside D

C30H46O12 (598.2989)

Rumphioside D

C29H42O13 (598.2625)

Wikstrotoxin A

C35H50O8 (598.3506)

C34H46O9

C34H46O9 (598.3142)

Piscidofuran

C33H42O10 (598.2778)

LL-F28249gamma|nemadectin B|S541 Factor A

C35H50O8 (598.3506)

salannol-3-acetate

C34H46O9 (598.3142)

Di-Ac-Flavidulol C

C38H46O6 (598.3294)

Mugil visceroactive peptide-1|SGPAGVLamide

C26H46N8O8 (598.3438)

5,7,14-triacetoxy-3-benzoyloxy-15-hydroxy-9-oxojatropha-6(17),11E-diene

C33H42O10 (598.2778)

(+)-Espinine

C35H38N2O7 (598.2679)

(24S)-3beta-hydroxy-24,25-oxiirane-16,23-dione-9,10-seco-9,19-cyclolanost-1(10),7(8),9(11)-trien 3-O-beta-D-xylopyranoside|isocimipodocarpaside

C35H50O8 (598.3506)

rehmaglutosides F

C30H46O12 (598.2989)

3,5-bis(3-methyl-2-butenyl)-4-O-[beta-D-glucopyranosyl-(1?4)-beta-D-glucopyranosyl]benzoic acid

C29H42O13 (598.2625)

formicinuoside A

C29H42O13 (598.2625)

munronoid N

C34H46O9 (598.3142)

3beta-benzoyloxy-15beta-hydroxy-7beta,8beta,9alpha-triacetoxy-14-oxo-2betaH,13alphaH-jatropha-5E,11E-diene|euphomelliferine

C33H42O10 (598.2778)

formicinuoside B

C29H42O13 (598.2625)

Antibiotic S541D

C35H50O8 (598.3506)

3-O-beta-D-xylopyranosylholosta-7,9(11),22E,24-tetraene-3beta,17alpha-diol|nobiliside A

C35H50O8 (598.3506)

C33H42O10

C33H42O10 (598.2778)

tedanolide C

C31H50O11 (598.3353)

Antibiotic S451B

C35H50O8 (598.3506)

(2S,3S,4R,5R,6R,8R,12S,13S,14R,15R)-5,8,14-triacetoxy-3-benzoyloxy-15-hydroxy-9-oxo-paraliane|5,8,14-triacetoxy-3-benzoyloxy-15-hydroxy-9-oyoparaliane|Paraliane 13|paraliane diterpene

C33H42O10 (598.2778)

C31H50O11

C31H50O11 (598.3353)

S541 Factor C

C35H50O8 (598.3506)

24,25-epoxy-1,7-diacetoxy-1alpha,7alpha-dihydroxy-14,18-cycloapotirucalla-20(22)-en-3,4:20,23-diolide|simaroubin C

C34H46O9 (598.3142)

VM-44864

C35H50O8 (598.3506)

Di-Ac-Serratamolide

C30H50N2O10 (598.3465)

24,25-epoxy-1,7-diacetoxy-1alpha,7alpha-dihydroxyapotirucalla-14,20(22)-dien-3,4:20,23-diolide|simaroubin D

C34H46O9 (598.3142)

3-O-[beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside]-5alpha,14alpha-androst-8-ene

C31H50O11 (598.3353)

1beta,8beta-diacetoxy-9beta-cinnamoyloxy-2beta-hexanoyloxy-beta-dihydroagarofuran

C34H46O9 (598.3142)

Hematoporphyrin_I

C34H38N4O6 (598.2791)

12b-O-[deca-2E,4Z-dienoyl]-13a-(2-methylbutyl)-4b-phorbol

C35H50O8 (598.3506)

12b-O-[deca-2Z,4E-dienoyl]-13a-isobutyl-5-ene-7-oxo-4b-phorbol

C34H46O9 (598.3142)

C33H42O10_1H-Cyclopent[a]-s-indacen-1-one, 4,8,9a-tris(acetyloxy)-7-(benzoyloxy)tetradecahydro-4a-hydroxy-2,2,3b,6,8a-pentamethyl-, (3aS,3bS,4R,4aR,6S,7S,7aR,8R,8aR,9aS)

C33H42O10 (598.2778)

Haematoporphyrin

C34H38N4O6 (598.2791)

Ala His Trp Trp

C31H34N8O5 (598.2652)

Ala Trp His Trp

C31H34N8O5 (598.2652)

Ala Trp Trp His

C31H34N8O5 (598.2652)

Glu His Lys Trp

C28H38N8O7 (598.2863)

Glu His Trp Lys

C28H38N8O7 (598.2863)

Glu Lys His Trp

C28H38N8O7 (598.2863)

Glu Lys Trp His

C28H38N8O7 (598.2863)

Glu Trp His Lys

C28H38N8O7 (598.2863)

Glu Trp Lys His

C28H38N8O7 (598.2863)

Phe Asn Arg Tyr

C28H38N8O7 (598.2863)

Phe Asn Tyr Arg

C28H38N8O7 (598.2863)

Phe Arg Asn Tyr

C28H38N8O7 (598.2863)

Phe Arg Tyr Asn

C28H38N8O7 (598.2863)

Phe Tyr Asn Arg

C28H38N8O7 (598.2863)

Phe Tyr Arg Asn

C28H38N8O7 (598.2863)

His Ala Trp Trp

C31H34N8O5 (598.2652)

His Glu Lys Trp

C28H38N8O7 (598.2863)

His Glu Trp Lys

C28H38N8O7 (598.2863)

His Lys Glu Trp

C28H38N8O7 (598.2863)

His Lys Trp Glu

C28H38N8O7 (598.2863)

His Met Arg Arg

C23H42N12O5S (598.3122)

His Arg Met Arg

C23H42N12O5S (598.3122)

His Arg Arg Met

C23H42N12O5S (598.3122)

His Arg Thr Trp

C27H38N10O6 (598.2976)

His Arg Trp Thr

C27H38N10O6 (598.2976)

His Thr Arg Trp

C27H38N10O6 (598.2976)

His Thr Trp Arg

C27H38N10O6 (598.2976)

His Trp Ala Trp

C31H34N8O5 (598.2652)

His Trp Glu Lys

C28H38N8O7 (598.2863)

His Trp Lys Glu

C28H38N8O7 (598.2863)

His Trp Arg Thr

C27H38N10O6 (598.2976)

His Trp Thr Arg

C27H38N10O6 (598.2976)

His Trp Trp Ala

C31H34N8O5 (598.2652)

Lys Glu His Trp

C28H38N8O7 (598.2863)

Lys Glu Trp His

C28H38N8O7 (598.2863)

Lys His Glu Trp

C28H38N8O7 (598.2863)

Lys His Trp Glu

C28H38N8O7 (598.2863)

Lys Trp Glu His

C28H38N8O7 (598.2863)

Lys Trp His Glu

C28H38N8O7 (598.2863)

Met His Arg Arg

C23H42N12O5S (598.3122)

Met Arg His Arg

C23H42N12O5S (598.3122)

Met Arg Arg His

C23H42N12O5S (598.3122)

Asn Phe Arg Tyr

C28H38N8O7 (598.2863)

Asn Phe Tyr Arg

C28H38N8O7 (598.2863)

Asn Arg Phe Tyr

C28H38N8O7 (598.2863)

Asn Arg Tyr Phe

C28H38N8O7 (598.2863)

Asn Tyr Phe Arg

C28H38N8O7 (598.2863)

Asn Tyr Arg Phe

C28H38N8O7 (598.2863)

Arg Phe Asn Tyr

C28H38N8O7 (598.2863)

Arg Phe Tyr Asn

C28H38N8O7 (598.2863)

Arg His Met Arg

C23H42N12O5S (598.3122)

Arg His Arg Met

C23H42N12O5S (598.3122)

Arg His Thr Trp

C27H38N10O6 (598.2976)

Arg His Trp Thr

C27H38N10O6 (598.2976)

Arg Met His Arg

C23H42N12O5S (598.3122)

Arg Met Arg His

C23H42N12O5S (598.3122)

Arg Asn Phe Tyr

C28H38N8O7 (598.2863)

Arg Asn Tyr Phe

C28H38N8O7 (598.2863)

Arg Arg His Met

C23H42N12O5S (598.3122)

Arg Arg Met His

C23H42N12O5S (598.3122)

Arg Thr His Trp

C27H38N10O6 (598.2976)

Arg Thr Trp His

C27H38N10O6 (598.2976)

Arg Trp His Thr

C27H38N10O6 (598.2976)

Arg Trp Thr His

C27H38N10O6 (598.2976)

Arg Tyr Phe Asn

C28H38N8O7 (598.2863)

Arg Tyr Asn Phe

C28H38N8O7 (598.2863)

Thr His Arg Trp

C27H38N10O6 (598.2976)

Thr His Trp Arg

C27H38N10O6 (598.2976)

Thr Arg His Trp

C27H38N10O6 (598.2976)

Thr Arg Trp His

C27H38N10O6 (598.2976)

Thr Trp His Arg

C27H38N10O6 (598.2976)

Thr Trp Arg His

C27H38N10O6 (598.2976)

Trp Ala His Trp

C31H34N8O5 (598.2652)

Trp Ala Trp His

C31H34N8O5 (598.2652)

Trp Glu His Lys

C28H38N8O7 (598.2863)

Trp Glu Lys His

C28H38N8O7 (598.2863)

Trp His Ala Trp

C31H34N8O5 (598.2652)

Trp His Glu Lys

C28H38N8O7 (598.2863)

Trp His Lys Glu

C28H38N8O7 (598.2863)

Trp His Arg Thr

C27H38N10O6 (598.2976)

Trp His Thr Arg

C27H38N10O6 (598.2976)

Trp His Trp Ala

C31H34N8O5 (598.2652)

Trp Lys Glu His

C28H38N8O7 (598.2863)

Trp Lys His Glu

C28H38N8O7 (598.2863)

Trp Arg His Thr

C27H38N10O6 (598.2976)

Trp Arg Thr His

C27H38N10O6 (598.2976)

Trp Thr His Arg

C27H38N10O6 (598.2976)

Trp Thr Arg His

C27H38N10O6 (598.2976)

Trp Trp Ala His

C31H34N8O5 (598.2652)

Trp Trp His Ala

C31H34N8O5 (598.2652)

Tyr Phe Asn Arg

C28H38N8O7 (598.2863)

Tyr Phe Arg Asn

C28H38N8O7 (598.2863)

Tyr Asn Phe Arg

C28H38N8O7 (598.2863)

Tyr Asn Arg Phe

C28H38N8O7 (598.2863)

Tyr Arg Phe Asn

C28H38N8O7 (598.2863)

Tyr Arg Asn Phe

C28H38N8O7 (598.2863)

PI(18:1/0:0)

C27H51O12P (598.3118)

LPI 18:1

C27H51O12P (598.3118)

PG-PG

C27H51O12P (598.3118)

H-Phe-Met-D-Arg-Phe-NH2

C29H42N8O4S (598.305)

Ethylene glycol,1,2-propanediol,trimethylolpropane diallyl ether,maleic anhydride,phthalic anhydride polymer

C29H42O13 (598.2625)

ISOHEMATOPORPHYRIN IX

C34H38N4O6 (598.2791)

Glicaramide

C30H42N6O5S (598.2937)

H-Phe-Met-Arg-Phe-NH2 acetate salt

C29H42N8O4S (598.305)

1,3,3-trimethyl-2-[2-[2-phenyl-3-[2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]cyclopent-2-en-1-ylidene]ethylidene]indole,tetrafluoroborate

C37H39BF4N2 (598.3142)

Rupintrivir

C31H39FN4O7 (598.2803)

D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C254 - Anti-Infective Agent > C281 - Antiviral Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

Desethyl Dabigatran Etexilate Carboxamide

C32H38N8O4 (598.3016)

C30H54O6SSi2

C30H54O6SSi2 (598.3179)

R-3,3-bis([1,1-biphenyl]-4-yl)-5,5,6,6,7,7,8,8-octahydro-[1,1-Binaphthalene]-2,2-diol

C44H38O2 (598.2872)

2,3-Dihydrosalannin

C34H46O9 (598.3142)

A limonoid that is the 2,3-dihydro derivative of salannin. It has been isolated from Azadirachta indica.

Forskoditerpenoside D

C30H46O12 (598.2989)

A diterpene glycoside that is labd-14-en-11-one substituted by beta-acetoxy groups at positions 6 and 7, an epoxy group between positions 8 and 13 and a beta-D-glucopyranosyloxy group at position 1 (the 1alpha stereoisomer). Isolated from the whole plant of Coleus forskohlii, it shows relaxative effects on isolated guinea pig tracheal spirals in vitro.

5,8,14-Triacetoxy-3-benzoyloxy-15-hydroxy-9-oxoparaliane

C33H42O10 (598.2778)

Berbamuninium(2+)

C36H42N2O6+2 (598.3043)

5-O-mycaminosyltylonolide(1+)

C31H52NO10+ (598.3591)

An organic cation that is the conjugate acid of 5-O-mycaminosyltylonolide, obtained by protonation of the tertiary amino group; major species at pH 7.3.

(1R)-1,2,3,4-tetrahydro-1-[[4-[2-hydroxy-5-[[(1R)-1,2,3,4-tetrahydro-7-hydroxy-6-methoxy-2-methyl-1-isoquinolinyl]methyl]phenoxy]phenyl]methyl]-6-methoxy-2-methyl-7-isoquinolinol

C36H42N2O6+2 (598.3043)

3-[(21S,22S)-12-(dihydroxymethyl)-11-ethyl-4-hydroxy-16-[(1R)-1-hydroxyethyl]-17,19,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,3,5,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid

C34H38N4O6 (598.2791)

4-[[2-[(4-Fluorophenyl)methyl]-6-methyl-5-[(5-methyl-3-isoxazolyl)carbonylamino]-1,4-dioxoheptyl]amino]-5-(2-oxo-3-pyrrolidinyl)-2-pentenoic acid ethyl ester

C31H39FN4O7 (598.2803)

1-Oleoylglycerophosphoinositol

C27H51O12P (598.3118)

PA(8:0/20:4(6E,8Z,11Z,14Z)+=O(5))

C31H51O9P (598.3271)

PA(20:4(6E,8Z,11Z,14Z)+=O(5)/8:0)

C31H51O9P (598.3271)

PA(8:0/20:4(5Z,8Z,11Z,13E)+=O(15))

C31H51O9P (598.3271)

PA(20:4(5Z,8Z,11Z,13E)+=O(15)/8:0)

C31H51O9P (598.3271)

PA(8:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))

C31H51O9P (598.3271)

PA(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/8:0)

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/8:0)

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/8:0)

C31H51O9P (598.3271)

PA(8:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))

C31H51O9P (598.3271)

PA(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/8:0)

C31H51O9P (598.3271)

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (E)-octadec-9-enoate

C27H51O12P (598.3118)

2-[3,4-Dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;hexadecanoic acid

C28H54O13 (598.3564)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

(1R,3R,4S,5S,6S,6S,8R,10E,13R,14E,16E,20R,21R,24S)-6-[(E)-But-2-en-2-yl]-3,24-dihydroxy-21-methoxy-5,11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2-oxane]-2-one

C35H50O8 (598.3506)

(4R,5R)-4-[[2-(azidomethyl)phenyl]methyl]-5-(2-azidophenyl)-2-[4-(3-hydroxypropoxy)phenyl]-N-(3-methoxypropyl)-5H-oxazole-4-carboxamide

C31H34N8O5 (598.2652)

(2R,3R,4S,5S,6R)-2-[[7-[[(2R,3R,4R,5S)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]oxy]-2-ethenyl-2,4b,8,8-tetramethyl-4,4a,5,6,7,8a,9,10-octahydro-3H-phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C31H50O11 (598.3353)

3-(1,3-benzodioxol-5-yl)-1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-1-methylurea

C34H38N4O6 (598.2791)

3-(1,3-benzodioxol-5-yl)-1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-1-methylurea

C34H38N4O6 (598.2791)

1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9R,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

1-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

3-(1,3-benzodioxol-5-yl)-1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-1-methylurea

C34H38N4O6 (598.2791)

3-(1,3-benzodioxol-5-yl)-1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-1-methylurea

C34H38N4O6 (598.2791)

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

C33H38N6O5 (598.2904)

4-(dimethylamino)-N-[[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3S,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

4-(dimethylamino)-N-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

1-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-phenylurea

C32H37F3N4O4 (598.2767)

4-(dimethylamino)-N-[(3R,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

1-[(3S,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

1-[(3R,9S,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9R,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9S,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9S,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

4-(dimethylamino)-N-[[(3S,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

1-[(3S,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

C33H38N6O5 (598.2904)

4-(dimethylamino)-N-[[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

C33H38N6O5 (598.2904)

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide

C33H38N6O5 (598.2904)

1-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-phenylurea

C32H37F3N4O4 (598.2767)

1-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-phenylurea

C32H37F3N4O4 (598.2767)

1-[(3R,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

4-(dimethylamino)-N-[[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[(3S,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

1-[(3R,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-phenylurea

C32H37F3N4O4 (598.2767)

4-(dimethylamino)-N-[[(3S,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9R,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9R,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

4-(dimethylamino)-N-[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[(3R,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

1-[(3R,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

4-(dimethylamino)-N-[[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3R,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

1-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-phenylurea

C32H37F3N4O4 (598.2767)

1-[(3S,9R,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

4-(dimethylamino)-N-[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3R,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-16-(methanesulfonamido)-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide

C29H50N4O7S (598.34)

4-(dimethylamino)-N-[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9R,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

1-[(3R,9R,10R)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

3-(1,3-benzodioxol-5-yl)-1-[[(3R,9S,10S)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

4-(dimethylamino)-N-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(methylsulfonyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide

C29H50N4O7S (598.34)

1-[(3S,9S,10S)-9-[[cyclopropylmethyl(methyl)amino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-(4-fluorophenyl)urea

C33H47FN4O5 (598.353)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9S,10R)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9S,10R)-16-(dimethylamino)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

3-(1,3-benzodioxol-5-yl)-1-[[(3S,9R,10S)-16-(dimethylamino)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-1-methylurea

C32H46N4O7 (598.3366)

3-(1,3-benzodioxol-5-yl)-1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-1-methylurea

C34H38N4O6 (598.2791)

3-(1,3-benzodioxol-5-yl)-1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-1-methylurea

C34H38N4O6 (598.2791)

1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-3-[(4-methoxyphenyl)methyl]-1-methylurea

C35H42N4O5 (598.3155)

3-(1,3-benzodioxol-5-yl)-1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-1-methylurea

C34H38N4O6 (598.2791)

12b-O-[deca-2Z,4E-dienoyl]-13a-isobutyl-5-ene-7-oxo-4b-phorbol

C34H46O9 (598.3142)

[(2R)-1-hydroxy-3-[hydroxy-[(2R,3R,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] (Z)-octadec-9-enoate

C27H51O12P (598.3118)

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (Z)-octadec-9-enoate

C27H51O12P (598.3118)

Dgdg O-8:0_4:0

C27H50O14 (598.32)

Dgdg O-9:0_3:0

C27H50O14 (598.32)

Smgdg O-16:1_2:0

C27H50O12S (598.3023)

Smgdg O-15:1_3:0

C27H50O12S (598.3023)

Smgdg O-13:1_5:0

C27H50O12S (598.3023)

Smgdg O-14:1_4:0

C27H50O12S (598.3023)

Dgdg O-10:0_2:0

C27H50O14 (598.32)

[1-[(2-acetyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C30H47O10P (598.2907)

[1-Acetyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] nonanoate

C26H46O15 (598.2837)

[1-Pentanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] hexanoate

C26H46O15 (598.2837)

[1-Propanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] octanoate

C26H46O15 (598.2837)

[1-Butanoyloxy-3-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] heptanoate

C26H46O15 (598.2837)

[1-acetyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C30H47O10P (598.2907)

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-tetradec-9-enoate

C26H47O13P (598.2754)

[1-butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-tridec-9-enoate

C26H47O13P (598.2754)

12b-O-[deca-2E,4Z-dienoyl]-13a-(2-methylbutyl)-4b-phorbol

C35H50O8 (598.3506)

[1-acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (Z)-pentadec-9-enoate

C26H47O13P (598.2754)

2-[hydroxy-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C31H53NO8P+ (598.3509)

2-[hydroxy-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-propanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C31H53NO8P+ (598.3509)

Berbamuninium(2+)

C36H42N2O6 (598.3043)

Dication of berbamunine arsing from protonation of both tertiary amino groups; major species at pH 7.3.

DGMG 12:0

C27H50O14 (598.32)

SQMG 19:0

C28H54O11S (598.3387)

DGGA 21:4;O

C30H46O12 (598.2989)

DGGA 22:3

C31H50O11 (598.3353)

PA 18:2/9:4;O2

C30H47O10P (598.2907)

PA 20:2/8:3;O

C31H51O9P (598.3271)

PA 20:3/7:3;O2

C30H47O10P (598.2907)

PA 20:4/7:2;O2

C30H47O10P (598.2907)

PA 20:4/8:1;O

C31H51O9P (598.3271)

PA 22:5/5:1;O2

C30H47O10P (598.2907)

PA 27:6;O2

C30H47O10P (598.2907)

PA 28:5;O

C31H51O9P (598.3271)

PG O-18:0/4:1;O2

C28H55O11P (598.3482)

PG O-22:1;O2

C28H55O11P (598.3482)

LPG 20:3;O4

C26H47O13P (598.2754)

PG 16:0/5:1;O2

C27H51O12P (598.3118)

PG 20:5/4:1

C30H47O10P (598.2907)

PG 22:6/2:0

C30H47O10P (598.2907)

PG 24:6

C30H47O10P (598.2907)

LPI 0:0/18:1

C27H51O12P (598.3118)

LPI 18:1/0:0

C27H51O12P (598.3118)

PI O-14:0/4:1

C27H51O12P (598.3118)

PI O-14:1/4:0

C27H51O12P (598.3118)

PI O-16:1/2:0

C27H51O12P (598.3118)

PI O-18:1

C27H51O12P (598.3118)

PI P-14:0/4:0

C27H51O12P (598.3118)

PI P-14:0/4:0 or PI O-14:1/4:0

C27H51O12P (598.3118)

PI P-16:0/2:0

C27H51O12P (598.3118)

PI P-16:0/2:0 or PI O-16:1/2:0

C27H51O12P (598.3118)

PI P-18:0

C27H51O12P (598.3118)

PI P-18:0 or PI O-18:1

C27H51O12P (598.3118)

PI 13:0/4:1

C26H47O13P (598.2754)

PI 15:1/2:0

C26H47O13P (598.2754)

PI 17:1

C26H47O13P (598.2754)

PI 17:1(9Z)/0:0

C26H47O13P (598.2754)

PEth 26:5;O

C31H51O9P (598.3271)

PM 27:5;O

C31H51O9P (598.3271)

ST 23:3;O7;GlcA

C29H42O13 (598.2625)

ST 24:2;O6;GlcA

C30H46O12 (598.2989)

ST 25:1;O5;GlcA

C31H50O11 (598.3353)

ST 27:7;O4;GlcA

C33H42O10 (598.2778)

ST 28:6;O3;GlcA

C34H46O9 (598.3142)

ST 29:5;O2;GlcA

C35H50O8 (598.3506)

ST 23:4;O8;Hex

C29H42O13 (598.2625)

ST 24:3;O7;Hex

C30H46O12 (598.2989)

ST 25:2;O6;Hex

C31H50O11 (598.3353)

ST 28:7;O4;Hex

C34H46O9 (598.3142)

ST 29:6;O3;Hex

C35H50O8 (598.3506)

Garsorasib

C32H32F2N8O2 (598.2616)

Garsorasib is a potent inhibitor of KRAS G12C with an IC50 of 10 nM. Garsorasib has the potential for the research of various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (non-small cell lung cancer) (extracted from patent WO2020233592A1, compound 2)[1].

LPI(18:1)

C27H51O12P (598.3118)

-

methyl 2-[6-(5-hydroxy-2-oxo-5h-furan-3-yl)-1,5,15,15-tetramethyl-14-[(3-methyl-2-oxopent-3-en-1-yl)oxy]-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-16-yl]acetate

C33H42O10 (598.2778)

4,11,13-tris(acetyloxy)-3a-hydroxy-2,5,8,8-tetramethyl-12-methylidene-9-oxo-1h,2h,3h,4h,5h,10h,11h,13h,13ah-cyclopenta[12]annulen-1-yl benzoate

C33H42O10 (598.2778)

2-{[(1-{2-[(3-amino-10-chloro-1,2-dihydroxydecylidene)amino]-3-hydroxybutanoyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-3-(4-hydroxyphenyl)propanoic acid

C28H43ClN4O8 (598.2769)

(1r,2r,8s,17r,19s)-12-hydroxy-8,21,21-trimethyl-5,19-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C38H46O6 (598.3294)

[3,4,5-tris(acetyloxy)-6-({4-[4-(acetyloxy)-2-hydroxy-2,6,6-trimethylcyclohexylidene]but-3-en-2-yl}oxy)oxan-2-yl]methyl acetate

C29H42O13 (598.2625)

2-({9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C31H50O11 (598.3353)

ethyl 6-[11-(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-3,7,10-trioxo-1h,2h,4h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxohept-5-enoate

C34H46O9 (598.3142)

(1r,2r,6s,7s,8r,10s,11s,12r,16r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-16-(prop-1-en-2-yl)-14-[(1e,3e)-tetradeca-1,3-dien-1-yl]-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-5-one

C35H50O8 (598.3506)

(3s,6r,15as)-9-[(2s)-butan-2-yl]-1,4,7-trihydroxy-6-[(4-methoxyphenyl)methyl]-3-[6-(oxiran-2-yl)-6-oxohexyl]-3h,6h,9h,12h,13h,14h,15h,15ah-pyrido[1,2-a]1,4,7,10-tetraazacyclododecan-10-one

C32H46N4O7 (598.3366)

(2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'e,20'r,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,24'-dihydroxy-21'-methoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C35H50O8 (598.3506)

5-hydroxy-2,6,13,17,17-pentamethyl-6-(4-methylpenta-1,3-dien-1-yl)-16-[(3,4,5-trihydroxyoxan-2-yl)oxy]-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-1(20),11-dien-8-one

C35H50O8 (598.3506)

6-[2-(acetyloxy)-8-hydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate

C34H46O9 (598.3142)

(1s,2s,3ar,4r,5r,11r,13r,13ar)-4,11,13-tris(acetyloxy)-3a-hydroxy-2,5,8,8-tetramethyl-12-methylidene-9-oxo-1h,2h,3h,4h,5h,10h,11h,13h,13ah-cyclopenta[12]annulen-1-yl benzoate

C33H42O10 (598.2778)

13-acetoxylbrevifoliol

C33H42O10 (598.2778)

{"Ingredient_id": "HBIN001123","Ingredient_name": "13-acetoxylbrevifoliol","Alias": "NA","Ingredient_formula": "C33H42O10","Ingredient_Smile": "CC1=C2C(C(C3(C(CC(C(=C)C3CC(C2(C)C)(CC1OC(=O)C)O)O)OC(=O)C4=CC=CC=C4)C)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25358","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

13-acetylbrevifoliol

C33H42O10 (598.2778)

{"Ingredient_id": "HBIN001126","Ingredient_name": "13-acetylbrevifoliol","Alias": "NA","Ingredient_formula": "C33H42O10","Ingredient_Smile": "CC1=C2C(C(C3(C(CC(C(=C)C3CC2(CC1OC(=O)C)C(C)(C)O)O)OC(=O)C)C)OC(=O)C)OC(=O)C4=CC=CC=C4","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "337","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

7β,16α-diacetoxy withanolide d

C33H42O10 (598.2778)

{"Ingredient_id": "HBIN013066","Ingredient_name": "7\u03b2,16\u03b1-diacetoxy withanolide d","Alias": "NA","Ingredient_formula": "C33H42O10","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5323","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

(2s,3as,4ar,6s,8s,8as,9r,10r)-2,8,9-tris(acetyloxy)-6-hydroxy-3a-(2-hydroxypropan-2-yl)-1,8a-dimethyl-5-methylidene-2h,3h,4h,4ah,6h,7h,8h,9h,10h-cyclohexa[f]azulen-10-yl benzoate

C33H42O10 (598.2778)

10-(acetyloxy)-16-[5-(3,3-dimethyloxiran-2-yl)-2-oxo-5h-furan-3-yl]-2,6,6,11-tetramethyl-8-oxo-7-oxapentacyclo[13.3.1.0¹,¹⁵.0²,¹².0⁵,¹¹]nonadecan-3-yl acetate

C34H46O9 (598.3142)

[(2r,3r,4s,5r,6r)-3,4,5-tris(acetyloxy)-6-{[(2r)-4-[(2r,4s)-4-(acetyloxy)-2-hydroxy-2,6,6-trimethylcyclohexylidene]but-3-en-2-yl]oxy}oxan-2-yl]methyl acetate

C29H42O13 (598.2625)

(1s,2r,3ar,4r,7s,11r,13as)-3a,4,11-tris(acetyloxy)-7-hydroxy-2,5,8,8,12-pentamethyl-9-oxo-1h,2h,3h,4h,7h,10h,11h,13ah-cyclopenta[12]annulen-1-yl benzoate

C33H42O10 (598.2778)

(1r,5r,6r,13r,14s,16s)-13-(acetyloxy)-6-(furan-3-yl)-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylpropanoate

C33H42O10 (598.2778)

(2s)-n-(5-carbamimidamido-1-oxopentan-2-yl)-2-{[(2r)-2-{[1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1-hydroxy-4-(4-hydroxyphenyl)butylidene]amino}-3-methylbutanimidic acid

C30H42N6O7 (598.3115)

(2s)-n-(5-carbamimidamido-1-hydroxypentan-2-yl)-1-[(2r)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl]pyrrolidine-2-carboximidic acid

C30H42N6O7 (598.3115)

5,7,9-tris(acetyloxy)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate

C34H46O9 (598.3142)

6-(but-2-en-2-yl)-3,24'-dihydroxy-21'-methoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C35H50O8 (598.3506)

(3s,6r,9s,15as)-9-[(2s)-butan-2-yl]-1,4,7-trihydroxy-6-[(4-methoxyphenyl)methyl]-3-{6-[(2s)-oxiran-2-yl]-6-oxohexyl}-3h,6h,9h,12h,13h,14h,15h,15ah-pyrido[1,2-a]1,4,7,10-tetraazacyclododecan-10-one

C32H46N4O7 (598.3366)

methyl (1r,2s,5s)-10,14-dihydroxy-2-(prop-1-en-2-yl)-16-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

C38H46O6 (598.3294)

methyl 10,14-dihydroxy-2-(prop-1-en-2-yl)-16-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

C38H46O6 (598.3294)

6-(but-2-en-2-yl)-3,21',24'-trihydroxy-5,11',13',18',22'-pentamethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C35H50O8 (598.3506)

5,8-bis(acetyloxy)-2,6,10,10-tetramethyl-7-[(3-phenylprop-2-enoyl)oxy]-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-4-yl hexanoate

C34H46O9 (598.3142)

(3e,6r)-6-[(1r,2r,3as,3bs,9ar,9br,11ar)-2-(acetyloxy)-8-hydroxy-3a,6,6,9b,11a-pentamethyl-7,10-dioxo-1h,2h,3h,3bh,4h,9ah,11h-cyclopenta[a]phenanthren-1-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate

C34H46O9 (598.3142)

6-(acetyloxy)-3-ethenyl-3,4a,7,7,10a-pentamethyl-1-oxo-10-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-octahydronaphtho[2,1-b]pyran-5-yl acetate

C30H46O12 (598.2989)

(1r,2r,4s,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-19-yl (2e)-2-methylbut-2-enoate

C34H46O9 (598.3142)

2,8,9-tris(acetyloxy)-6-hydroxy-3a-(2-hydroxypropan-2-yl)-1,8a-dimethyl-5-methylidene-2h,3h,4h,4ah,6h,7h,8h,9h,10h-cyclohexa[f]azulen-10-yl benzoate

C33H42O10 (598.2778)

(8r,9s,10r,11r)-11-hydroxy-4,5,14,15,16-pentamethoxy-9,10-dimethyl-8-{[(2z)-2-methylbut-2-enoyl]oxy}tricyclo[10.4.0.0²,⁷]hexadeca-1(12),2(7),3,5,13,15-hexaen-3-yl (2z)-2-methylbut-2-enoate

C33H42O10 (598.2778)

9,10,13-tris(acetyloxy)-1,5-dihydroxy-8,12,15,15-tetramethyl-4-methylidenetricyclo[9.3.1.0³,⁸]pentadec-11-en-7-yl benzoate

C33H42O10 (598.2778)

18-(acetyloxy)-6-(furan-3-yl)-13-hydroxy-1,5,12,17-tetramethyl-8-oxo-7,10,15-trioxahexacyclo[12.6.1.0²,¹².0⁵,¹¹.0⁹,¹¹.0¹⁷,²¹]henicosan-20-yl 2-methylbut-2-enoate

C33H42O10 (598.2778)

(1r,2r,3s,8r,10r,11r,15r,16s)-3-(acetyloxy)-15-[(5s)-5-[(2r)-3,3-dimethyloxiran-2-yl]-2-oxo-5h-furan-3-yl]-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-12-en-10-yl acetate

C34H46O9 (598.3142)

ethyl 6-[(1r,3ar,4s,5ar,9as,11s,11ar)-11-(acetyloxy)-4-hydroxy-3a,6,6,9a,11a-pentamethyl-3,7,10-trioxo-1h,2h,4h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxohept-5-enoate

C34H46O9 (598.3142)

(1'r,2r,4s,4's,5s,6s,8'r,10'e,13'r,14'e,16'e,20'r,21'r,24's)-6-[(2e)-but-2-en-2-yl]-4,24'-dihydroxy-21'-methoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C35H50O8 (598.3506)

(2s,3r,4s,5s,6r)-2-{[(2r,3r,4s,5r,6r)-2-{[(3ar,5as,7s,9as,11as)-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C31H50O11 (598.3353)

(1s,3s,4s,9s,10s,13s,15s,17s,18s,19s,24s,25s)-25-(acetyloxy)-4,8,8,19,23,23-hexamethyl-2,14,16,28,29-pentaoxaoctacyclo[15.10.1.1¹³,¹⁸.0³,¹².0³,¹⁵.0⁴,⁹.0¹⁸,²⁷.0¹⁹,²⁴]nonacosa-11,26-dien-10-yl acetate

C34H46O9 (598.3142)

(8r,9s,10r,11r)-11-hydroxy-4,5,14,15,16-pentamethoxy-9,10-dimethyl-8-{[(2z)-2-methylbut-2-enoyl]oxy}tricyclo[10.4.0.0²,⁷]hexadeca-1(12),2(7),3,5,13,15-hexaen-3-yl 2-methylbut-2-enoate

C33H42O10 (598.2778)

(3ar,3bs,4r,4as,5r,6r,7s,7ar,8r,8ar,9ar)-4,5,8-tris(acetyloxy)-4a-hydroxy-2,2,3b,6,8a-pentamethyl-1-oxo-decahydrocyclopenta[a]s-indacen-7-yl benzoate

C33H42O10 (598.2778)

2-methyl-n-[(2r)-1-oxo-1-{[(5r,6e,8e,10e,13s,14s,15r,16e)-3,15,22,24-tetrahydroxy-5-methoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(24),2,6,8,10,16,20,22-octaen-13-yl]oxy}propan-2-yl]propanimidic acid

C33H46N2O8 (598.3254)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 3,5-bis(3-methylbut-2-en-1-yl)-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzoate

C29H42O13 (598.2625)

(2r,3r,4s,5s,6r)-2-{[(3ar,5as,7s,9as,11as)-9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxane-3,4,5-triol

C31H50O11 (598.3353)

3-(acetyloxy)-15-[5-(3,3-dimethyloxiran-2-yl)-2-oxo-5h-furan-3-yl]-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadec-12-en-10-yl acetate

C34H46O9 (598.3142)

4,5,8-tris(acetyloxy)-4a-hydroxy-2,2,3b,6,8a-pentamethyl-1-oxo-decahydrocyclopenta[a]s-indacen-7-yl benzoate

C33H42O10 (598.2778)

(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-19-yl (2e)-2-methylbut-2-enoate

C34H46O9 (598.3142)

2-{[2-({2-[(2-{[(1-{2-[(2-amino-1,3-dihydroxypropylidene)amino]acetyl}pyrrolidin-2-yl)(hydroxy)methylidene]amino}-1-hydroxypropylidene)amino]-1-hydroxyethylidene}amino)-1-hydroxy-3-methylbutylidene]amino}-4-methylpentanimidic acid

C26H46N8O8 (598.3438)

(1r,2r,4r,6r,8r,11r,12s,13r,16r,17r,19s,20r)-17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-19-yl (2e)-2-methylbut-2-enoate

C34H46O9 (598.3142)

(2s)-2-{[(2s)-2-[(2-{[(2s)-2-({[(2r)-1-(2-{[(2s)-2-amino-1,3-dihydroxypropylidene]amino}acetyl)pyrrolidin-2-yl](hydroxy)methylidene}amino)-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-1-hydroxy-3-methylbutylidene]amino}-4-methylpentanimidic acid

C26H46N8O8 (598.3438)

3-[(2r,5s,8s,11r,14s)-3,6,9,12,15-pentahydroxy-14-(1h-indol-3-ylmethyl)-8-isopropyl-5-methyl-11-(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1(15),3,6,9,12-pentaen-2-yl]propanoic acid

C30H42N6O7 (598.3115)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 3,5-bis(3-methylbut-2-en-1-yl)-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}benzoate

C29H42O13 (598.2625)

(3as,3bs,4ar,6s,7s,7ar,8r,8ar,9as)-4,8,9a-tris(acetyloxy)-4a-hydroxy-2,2,3b,6,8a-pentamethyl-1-oxo-octahydro-3h-cyclopenta[a]s-indacen-7-yl benzoate

C33H42O10 (598.2778)

n-(5-carbamimidamido-1-hydroxypentan-2-yl)-1-(2-{[1,2-dihydroxy-4-(4-hydroxyphenyl)butylidene]amino}-3-(4-hydroxyphenyl)propanoyl)pyrrolidine-2-carboximidic acid

C30H42N6O7 (598.3115)

2-{[6-({4-hydroxy-6-[(6-hydroxy-4-methoxy-2-methyloxan-3-yl)oxy]-2-methyloxan-3-yl}oxy)-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C26H46O15 (598.2837)

n-(5-carbamimidamido-1-hydroxypentan-2-yl)-1-[(2s)-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}-4-(4-hydroxyphenyl)butanoyl]pyrrolidine-2-carboximidic acid

C30H42N6O7 (598.3115)

2',3'-dihydrosalannin

C34H46O9 (598.3142)

(1ar,3s,3ar,4r,5r,6r,7as)-5-(acetyloxy)-3-(furan-3-yl)-6-[(3r,4r)-3-(2-methoxy-2-oxoethyl)-2,2,4-trimethyl-7-oxo-3h-oxepin-4-yl]-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxiren-4-yl 2-methylpropanoate

C33H42O10 (598.2778)

12-hydroxy-8,21,21-trimethyl-5,19-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C38H46O6 (598.3294)

(1r,2r,5s,6s,9s,11r,12s,13s,14r,17r,18r,20s,21r)-18-(acetyloxy)-6-(furan-3-yl)-13-hydroxy-1,5,12,17-tetramethyl-8-oxo-7,10,15-trioxahexacyclo[12.6.1.0²,¹².0⁵,¹¹.0⁹,¹¹.0¹⁷,²¹]henicosan-20-yl (2e)-2-methylbut-2-enoate

C33H42O10 (598.2778)

2-{[2-({9a,11a-dimethyl-1h,2h,3h,3ah,4h,5h,5ah,6h,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C31H50O11 (598.3353)

(2s,5r,6s,9r,13s,16s,18r)-5-hydroxy-2,6,13,17,17-pentamethyl-6-[(1e)-4-methylpenta-1,3-dien-1-yl]-16-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-7-oxapentacyclo[10.8.0.0²,⁹.0⁵,⁹.0¹³,¹⁸]icosa-1(20),11-dien-8-one

C35H50O8 (598.3506)

13-(acetyloxy)-6-(furan-3-yl)-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylpropanoate

C33H42O10 (598.2778)

(1s,4ar,5r,7s,7as)-7-hydroxy-7-methyl-1-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,6h,7ah-cyclopenta[c]pyran-5-yl (2e,4e)-5-[(1r,2r)-1,2-dihydroxy-2,6,6-trimethylcyclohexyl]-3-methylpenta-2,4-dienoate

C30H46O12 (598.2989)

(3as,3bs,4r,4ar,6s,7s,7ar,8r,8ar,9as)-4,8,9a-tris(acetyloxy)-4a-hydroxy-2,2,3b,6,8a-pentamethyl-1-oxo-octahydro-3h-cyclopenta[a]s-indacen-7-yl benzoate

C33H42O10 (598.2778)

(1'r,2s,3r,4's,5s,6s,8'r,10'z,13'r,14'z,16'z,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,21',24'-trihydroxy-5,11',13',18',22'-pentamethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C35H50O8 (598.3506)

3-[3,6,9,12,15-pentahydroxy-14-(1h-indol-3-ylmethyl)-8-isopropyl-5-methyl-11-(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1(15),3,6,9,12-pentaen-2-yl]propanoic acid

C30H42N6O7 (598.3115)

ethyl (6r)-6-[(1r,3ar,5ar,9as,11s,11ar)-11-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoate

C34H46O9 (598.3142)

14-(acetyloxy)-6-(furan-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl 3-methylbutanoate

C34H46O9 (598.3142)

(2r,3s,4s,5r,6r)-2-({[(2r,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-{[(1s,4s,5s,6s,9s,10r,13r)-6-hydroxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methoxy}oxane-3,4,5-triol

C31H50O11 (598.3353)

4,8,9a-tris(acetyloxy)-4a-hydroxy-2,2,3b,6,8a-pentamethyl-1-oxo-octahydro-3h-cyclopenta[a]s-indacen-7-yl benzoate

C33H42O10 (598.2778)

5-(acetyloxy)-3-(furan-3-yl)-6-[3-(2-methoxy-2-oxoethyl)-2,2,4-trimethyl-7-oxo-3h-oxepin-4-yl]-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxiren-4-yl 2-methylpropanoate

C33H42O10 (598.2778)

methyl 2-[(1r,2s,5r,6r,10s,14r,16s)-6-(5-hydroxy-2-oxo-5h-furan-3-yl)-1,5,15,15-tetramethyl-14-{[(3e)-3-methyl-2-oxopent-3-en-1-yl]oxy}-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-16-yl]acetate

C33H42O10 (598.2778)

(1s,2s,8r,17s,19r)-12-hydroxy-8,21,21-trimethyl-5,19-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C38H46O6 (598.3294)

(1r,3br,4s,5r,5as,7r,9s,9ar,9br,11as)-4,7,9-tris(acetyloxy)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-1h,2h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate

C34H46O9 (598.3142)

(1s,2r,3ar,4r,7r,11r,13as)-3a,4,11-tris(acetyloxy)-7-hydroxy-2,5,8,8,12-pentamethyl-9-oxo-1h,2h,3h,4h,7h,10h,11h,13ah-cyclopenta[12]annulen-1-yl benzoate

C33H42O10 (598.2778)

(2s,8r,17s)-12-hydroxy-8,21,21-trimethyl-5,19-bis(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)-3,7,20-trioxahexacyclo[15.4.1.0²,¹⁵.0²,¹⁹.0⁴,¹³.0⁶,¹¹]docosa-4(13),5,9,11,15-pentaene-14,18-dione

C38H46O6 (598.3294)

4,15-dimethoxy-2,6,14,17-tetramethyl-3-oxo-11-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-16-yl acetate

C30H46O12 (598.2989)

(1ar,3s,3ar,4r,5r,6r,7as)-5-(acetyloxy)-3-(furan-3-yl)-6-[(3r,4s)-3-(2-methoxy-2-oxoethyl)-2,2,4-trimethyl-7-oxo-3h-oxepin-4-yl]-3a-methyl-7-methylidene-hexahydroindeno[1,7a-b]oxiren-4-yl 2-methylpropanoate

C33H42O10 (598.2778)

(2s)-n-[(2r)-5-carbamimidamido-1-hydroxypentan-2-yl]-1-[(2r)-2-{[1,2-dihydroxy-4-(4-hydroxyphenyl)butylidene]amino}-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboximidic acid

C30H42N6O7 (598.3115)

(1r,2s,4s,6r,9r,10r,11r,12s,14r,15r,18r)-14-(acetyloxy)-6-(furan-3-yl)-10-(2-methoxy-2-oxoethyl)-7,9,11,15-tetramethyl-3,17-dioxapentacyclo[9.6.1.0²,⁹.0⁴,⁸.0¹⁵,¹⁸]octadec-7-en-12-yl 3-methylbutanoate

C34H46O9 (598.3142)

(2s,3r,4s,5s,6r)-2-{[(2s,3r,4s,6r)-6-{[(2r,3s,4s,6r)-4-hydroxy-6-{[(2r,3s,4r,6s)-6-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C26H46O15 (598.2837)

(1s,2r,4s,5r,6s,7s,8r,9s)-5,8-bis(acetyloxy)-2,6,10,10-tetramethyl-7-{[(2e)-3-phenylprop-2-enoyl]oxy}-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-4-yl hexanoate

C34H46O9 (598.3142)

ethyl 6-[11-(acetyloxy)-3a,6,6,9a,11a-pentamethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methyl-4-oxoheptanoate

C34H46O9 (598.3142)

2-({[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}methyl)-6-({6-hydroxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl}methoxy)oxane-3,4,5-triol

C31H50O11 (598.3353)

(1s,2r,3r,5r,10s,11r,12r,15r,16r)-10-(acetyloxy)-16-[(5s)-5-[(2r)-3,3-dimethyloxiran-2-yl]-2-oxo-5h-furan-3-yl]-2,6,6,11-tetramethyl-8-oxo-7-oxapentacyclo[13.3.1.0¹,¹⁵.0²,¹².0⁵,¹¹]nonadecan-3-yl acetate

C34H46O9 (598.3142)

(1s,2s,3r,5r,6r,10s,13s,14r,16s)-3-(acetyloxy)-6-(furan-3-yl)-16-(2-methoxy-2-oxoethyl)-1,5,15,15-tetramethyl-8,17-dioxo-7-oxatetracyclo[11.3.1.0²,¹¹.0⁵,¹⁰]heptadec-11-en-14-yl 2-methylpropanoate

C33H42O10 (598.2778)

(1s,2s,6s,7s,9r,11s,13s,14r,15s,16s,17s)-4,15-dimethoxy-2,6,14,17-tetramethyl-3-oxo-11-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-10-oxatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadec-4-en-16-yl acetate

C30H46O12 (598.2989)

(2s)-n-[(2s)-5-carbamimidamido-1-hydroxypentan-2-yl]-1-[(2r)-2-{[1,2-dihydroxy-4-(4-hydroxyphenyl)butylidene]amino}-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboximidic acid

C30H42N6O7 (598.3115)

3a,4,11-tris(acetyloxy)-7-hydroxy-2,5,8,8,12-pentamethyl-9-oxo-1h,2h,3h,4h,7h,10h,11h,13ah-cyclopenta[12]annulen-1-yl benzoate

C33H42O10 (598.2778)

17-(acetyloxy)-8-(furan-3-yl)-12-hydroxy-4-methoxy-1,9,11,16-tetramethyl-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-19-yl 2-methylbut-2-enoate

C34H46O9 (598.3142)